Core Viewpoint - Chongqing Huasen Pharmaceutical Co., Ltd. has received approval from the Chongqing Municipal Drug Administration for the re-registration of one chemical raw material (Dipotassium Glycyrrhizinate) and one drug (Sodium Ferulate Injection) [1] Group 1: Product Approvals - The re-registration approval includes a notification for the chemical raw material Dipotassium Glycyrrhizinate, which is used for the production of Glycyrrhizinate Injection [1] - The Sodium Ferulate Injection is indicated for the auxiliary treatment of ischemic cardiovascular and cerebrovascular diseases [1] Group 2: Impact on Operations - The re-registration approval will ensure the normal production and sales of the related drugs [1] - The company will strictly control product quality [1] - However, there is no significant short-term impact on the company's operating performance [1]

Core Points - Chongqing Huasen Pharmaceutical Co., Ltd. has received approval from the Chongqing Municipal Drug Administration for the re-registration of two drugs: Pediatric Throat Granules and Diammonium Glycyrrhizinate for Injection [1][2][6] Group 1: Drug Registration Information - Pediatric Throat Granules are indicated for clearing heat and relieving throat pain, used for children with symptoms such as sore throat, cough with phlegm, and acute pharyngitis [2][4] - Diammonium Glycyrrhizinate for Injection is used for acute and chronic viral hepatitis with elevated alanine aminotransferase (ALT) levels, exhibiting anti-inflammatory and hepatoprotective effects [3][5] Group 2: Market Context - The pediatric traditional Chinese medicine market has reached a record high of 18.3 billion yuan in 2024, with pediatric cold medications accounting for 37.23% and cough medications for 34.40% of the market share [4] Group 3: Company Impact - The approval of the re-registration will ensure the normal production and sales of the drugs, allowing the company to maintain high product quality [6]

Core Viewpoint - Huason Pharmaceutical has received drug re-registration approval for two products, indicating a positive development in its product portfolio and market presence [1][2]. Group 1: Product Details - The company received approval for "Pediatric Throat and Tonsil Granules," which is used for treating symptoms like sore throat and cough in children [1]. - The second product, "Injectable Glycyrrhizin Ammonium," is indicated for acute and chronic viral hepatitis with elevated ALT levels, showcasing its comprehensive liver protection effects [2]. Group 2: Market Insights - The pediatric traditional Chinese medicine market in China is projected to reach 18.3 billion yuan in 2024, with pediatric cold medications accounting for 37.23% and cough medications for 34.40% of the market share [1]. - The approval of these products aligns with the growing demand for pediatric medications, particularly in the context of rising sales in the sector [1]. Group 3: Regulatory and Quality Assurance - The approval ensures the normal production and sales of the mentioned drugs, with the company committing to strict quality control measures [2]. - The injectable glycyrrhizin ammonium has been included in several national and international liver disease management guidelines, reinforcing its credibility and market position [2].

Group 1 - The company, Huason Pharmaceutical, announced the receipt of two drug re-registration approval notices from the Chongqing Drug Administration [2] - The approved drugs include Pediatric Pharyngeal Tonsil Granules and Injection Glycyrrhizic Acid Disodium [2]